Resistance to the ABL kinase inhibitor imatinib (STI571 or Gleevec) in chronic myeloid leukemia
(CML) occurs through selection for tumor cells harboring BCR-ABL kinase domain point …

Background The BCR-ABL tyrosine kinase inhibitor imatinib is effective in Philadelphia
chromosome–positive (Ph-positive) leukemias, but relapse occurs, mainly as a result of the …

Through sequencing analysis of blood or bone marrow samples from patients with chronic
myeloid leukemia, we identified BCR-ABL kinase domain mutations in 29 of 32 patients …

Background Treatment with dasatinib, a highly potent BCR-ABL kinase inhibitor, has
resulted in high rates of complete cytogenetic response and progression-free survival among …

The clinical success of the ABL tyrosine kinase inhibitor imatinib in chronic myeloid leukaemia
(CML) serves as a model for molecularly targeted therapy of cancer 1 , 2 , 3 , 4 , but at …

Background Resistance to tyrosine kinase inhibitors in patients with chronic myeloid
leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph-positive …

Purpose We report the 5-year analysis from the phase III Dasatinib Versus Imatinib Study in
Treatment-Naïve Chronic Myeloid Leukemia Patients (DASISION) trial, evaluating long-term …

… In a study of AC220 (quizartinib), an FLT3 kinase inhibitor that is currently being evaluated
in clinical trials for people with AML, Neil Shah and colleagues have identified secondary …

Genomic profiling has identified a subtype of high-risk B-progenitor acute lymphoblastic
leukemia (B-ALL) with alteration of IKZF1, a gene expression profile similar to BCR-ABL1-…

Although imatinib induces marked responses in patients with chronic myeloid leukemia (CML),
resistance is increasingly problematic, and treatment options for imatinib-resistant or -…